The mid-gestation triple test profile among women diagnosed with vasa previa

Abstract Purpose: To assess the mid-trimester triple test biomarkers among women diagnosed with vasa previa (VP). Methods: The study included 43 singleton pregnancies diagnosed with vasa previa between the years 1988 and 2011. The mid-gestation screening test for Down syndrome was calculated from the combination of triple serum markers and maternal age, and expressed as a multiple of the gestation specific normal mean (MoM). Reference MoM values were calculated from the local population. The levels of mid-gestation maternal serum alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE3) of patients with VP were compared with control reference group. Results: The mean hCG and αFP levels of women diagnosed with VP was significantly higher compared to control reference group (1.42 versus 0.99 MoM; p < .002 and 1.24 versus1.01 MoM; p < .001, respectively). In contrast, there was no significant difference in uE3 levels between these two groups (0.99 versus 0.98 MoM; p = .71). Conclusions: Our findings suggest that increased mid-gestation hCG and AFP were found among pregnancies complicated with VP. Clinicians should consider targeted scanning of pregnant women with risk factors for VP, including unexplained high maternal levels of hCG and αFP of the triple test, while conducting mid-gestation anomaly scan.

[1]  J. Dashe,et al.  #37: Diagnosis and Management of Vasa Previa , 2016 .

[2]  J. Limpens,et al.  Incidence of and risk indicators for vasa praevia: a systematic review , 2016, BJOG : an international journal of obstetrics and gynaecology.

[3]  D. Kidron,et al.  Is the ratio of maternal serum to amniotic fluid AFP superior to serum levels as a predictor of pregnancy complications? , 2016, Archives of Gynecology and Obstetrics.

[4]  C. Ananth,et al.  Placental implantation abnormalities and risk of preterm delivery: a systematic review and metaanalysis. , 2015, American journal of obstetrics and gynecology.

[5]  C. Ananth,et al.  Using ultrasound in the clinical management of placental implantation abnormalities. , 2015, American journal of obstetrics and gynecology.

[6]  R. Silver.  Abnormal Placentation: Placenta Previa, Vasa Previa, and Placenta Accreta. , 2015, Obstetrics and gynecology.

[7]  J. Derks,et al.  Systematic review of accuracy of ultrasound in the diagnosis of vasa previa , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[8]  J. Hasegawa.  Sonoembryological evaluations of the development of placenta previa and velamentous cord insertion , 2015, The journal of obstetrics and gynaecology research.

[9]  T. Kiserud,et al.  Prevalence, Risk Factors and Outcomes of Velamentous and Marginal Cord Insertions: A Population-Based Study of 634,741 Pregnancies , 2013, PloS one.

[10]  J. Bar,et al.  The effect of hereditary versus acquired thrombophilia on triple test Down's syndrome screening , 2013, Prenatal diagnosis.

[11]  E. Jauniaux,et al.  Do assisted-reproduction twin pregnancies require additional antenatal care? , 2013, Reproductive biomedicine online.

[12]  V. Belogolovkin,et al.  Abnormal Placentation: Evidence-Based Diagnosis and Management of Placenta Previa, Placenta Accreta, and Vasa Previa , 2012, Obstetrical & gynecological survey.

[13]  J. Bar,et al.  Does low molecular weight heparin influence the triple test result in pregnant women with thrombophilia? , 2012, The Israel Medical Association journal : IMAJ.

[14]  A. Herman,et al.  Is neonatal risk from vasa previa preventable? The 20‐year experience from a single medical center , 2010, Journal of clinical ultrasound : JCU.

[15]  S. Goetgeluk,et al.  Umbilical cord anomalies are more frequent in twins after assisted reproduction. , 2007, Human reproduction.

[16]  N. Maiz,et al.  Prenatal ultrasound diagnosis of vasa praevia and analysis of risk factors , 2007, Prenatal diagnosis.

[17]  A. Halstead,et al.  Second‐trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies , 2005, Prenatal diagnosis.

[18]  V. Catanzarite,et al.  Vasa Previa: The Impact of Prenatal Diagnosis on Outcomes , 2004, Obstetrics and gynecology.

[19]  A. Beauchet,et al.  Medically assisted reproduction and second‐trimester maternal serum marker screening for Down syndrome , 2003, Prenatal diagnosis.

[20]  L. Dodds,et al.  Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. , 2003, American journal of obstetrics and gynecology.

[21]  How-Ran Guo,et al.  Placental sonolucency and pregnancy outcome in women with elevated second trimester serum alpha-fetoprotein levels. , 2003, Journal of the Formosan Medical Association = Taiwan yi zhi.

[22]  R. Ron-el,et al.  In vitro fertilization is a risk factor for vasa previa. , 2002, Fertility and sterility.

[23]  L. Wilkins-Haug.  Unexplained elevated maternal serum alpha-fetoprotein: what is the appropriate follow-up? , 1998, Current opinion in obstetrics & gynecology.

[24]  L. Morssink,et al.  PLACENTAL MOSAICISM IS ASSOCIATED WITH UNEXPLAINED SECOND‐TRIMESTER ELEVATION OF MShCG LEVELS, BUT NOT WITH ELEVATION OF MSAFP LEVELS , 1996, Prenatal diagnosis.

[25]  J. Rodis,et al.  Predicting pregnancy outcome from the degree of maternal serum alpha-fetoprotein elevation. , 1996, The Journal of reproductive medicine.

[26]  D. Nyberg,et al.  Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. , 1992, American journal of obstetrics and gynecology.

[27]  E. Jauniaux,et al.  Pathologic Features of Placentas From Singleton Pregnancies Obtained by In Vitro Fertilization and Embryo Transfer , 1990, Obstetrics and gynecology.

[28]  Sonography of Placental Abnormalities and Oligohydramnios in Women with Elevated Alphafetoprotein Levels: Comparison with Control Subjects , 1990 .

[29]  D. Nyberg,et al.  Sonography of placental abnormalities and oligohydramnios in women with elevated alpha-fetoprotein levels: comparison with control subjects. , 1989, AJR. American journal of roentgenology.

[30]  C. Salafia,et al.  Placental pathology at term associated with elevated midtrimester maternal serum alpha-fetoprotein concentration. , 1988, American journal of obstetrics and gynecology.

[31]  K. Benirschke,et al.  Pathology of the Human Placenta , 1974, Springer New York.

[32]  H. Fox.  Effect of hypoxia on trophoblast in organ culture. A morphologic and autoradiographic study. , 1970, American journal of obstetrics and gynecology.

[33]  R. Gagnon,et al.  SOGC CLINICAL PRACTICE GUIDELINE: guidelines for the management of vasa previa. , 2010, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.